search
Back to results

Impact of Per Oral Pyloromyotomy (POP) on Glycemic Control in Diabetes

Primary Purpose

Diabetes Mellitus, Gastroparesis With Diabetes Mellitus, Gastroparesis

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Pyloromyotomy
Sponsored by
Matthew Allemang
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Diabetes Mellitus

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patients 18 years of age and older
  2. Patients with gastroparesis with an average HbA1c> 7.5% over the past 3 months
  3. Patient that have a diagnosis of gastroparesis established by documented delayed gastric emptying by either a wireless motility capsule study or a nuclear gastric emptying study, with no evidence of gastric obstruction.
  4. Patients are able to complete all study requirements

Exclusion Criteria:

  1. Patients <18 years of age
  2. Patients with gastroparesis with an average HbA1c< 7.5% over the past 3 months
  3. Patients unable or refuse to complete the study requirements
  4. Patients who are unable or refuse to wear a CGM sensor
  5. Patients with insulin pumps
  6. Patients who already use a CGM

Sites / Locations

  • Cleveland Clinic FoundationRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Endoscopic Per-Oral Pyloromyotomy (POP)

Arm Description

The study cohort will include 40 patients with a HbA1c >7.5% with medically refractory gastroparesis who are scheduled to undergo POP. Each patient will undergo two 10-day periods of CGM at an interval of approximately seven months, one month prior to the procedure and six months after. Symptoms and diabetes management improvement will be measured by the Gastroparesis Cardinal Symptom Index (GCSI) scores and the Diabetes Self-Management Questionnaire (DSMQ).

Outcomes

Primary Outcome Measures

Change from Baseline in Hemoglobin A1C levels
Glycemic control will be evaluated by measuring change in Hemoglobin A1C (HbA1c) levels. Poor glycemic control defined as an average HbA1c > 7.5%. Change = (Six Month Score - Baseline Score)
Change from Baseline in Glucose Levels measured by Continuous Glucose Monitor
Glycemic control will be evaluated by measuring average glucose levels using Continuous Glucose Monitors (CGM). Normal glucose levels 74-99 mg/dL. Change = (Six Month Score - Baseline Score)

Secondary Outcome Measures

Change from Baseline on Diabetes Self-Management Questionnaire
The Diabetes Self-Management Questionnaire (DSMQ) is a self reported instrument assessing diabetes self-care activities. Possible scores range from 0 (Does not apply) to 3 (Applies to me very much). Change = (Six Month Score - Baseline Score)
Change from Baseline on Gastroparesis Cardinal Symptom Index
The Gastroparesis Cardinal Symptom Index (GCSI) is a validated patient-administered questionnaire that is used to assess gastroparesis symptom severity. Possible scores range from 0 (None) to 5 (Very Severe). Change = (Six Month Score - Baseline Score)

Full Information

First Posted
August 14, 2020
Last Updated
January 17, 2023
Sponsor
Matthew Allemang
Collaborators
Society of American Gastrointestinal and Endoscopic Surgeons
search

1. Study Identification

Unique Protocol Identification Number
NCT04696159
Brief Title
Impact of Per Oral Pyloromyotomy (POP) on Glycemic Control in Diabetes
Official Title
Impact of Endoscopic Per-Oral Pyloromyotomy (POP) on Glycemic Control in Gastroparesis Patients With Poorly Controlled Diabetes Mellitus
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 4, 2023 (Actual)
Primary Completion Date
May 2024 (Anticipated)
Study Completion Date
May 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Matthew Allemang
Collaborators
Society of American Gastrointestinal and Endoscopic Surgeons

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study will assess changes in glycemic control in 40 patients with diabetes who undergo per-oral pyloromyotomy (POP) for medically refractory gastroparesis.
Detailed Description
This will be a prospective study using HbA1c values and continuous glucose monitoring (CGM) to assess changes in glycemic control in patients with diabetes who undergo per-oral pyloromyotomy (POP) for medically refractory gastroparesis. The study cohort will consist of 40 patients with poor glycemic control who undergo POP. The investigators propose a prospective cohort study using CGM to compare glycemic profiles before and after POP in patients with diabetic gastroparesis. The investigators hypothesize that patients will have improvement in glycemic control and reduced variation in blood glucose levels (% time in hypo/hyperglycemia) after undergoing POP. These results will aid in clinical decision making, and may indicate an earlier need for endoscopic intervention in patients with uncontrolled diabetes and gastroparesis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Gastroparesis With Diabetes Mellitus, Gastroparesis

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Endoscopic Per-Oral Pyloromyotomy (POP)
Arm Type
Experimental
Arm Description
The study cohort will include 40 patients with a HbA1c >7.5% with medically refractory gastroparesis who are scheduled to undergo POP. Each patient will undergo two 10-day periods of CGM at an interval of approximately seven months, one month prior to the procedure and six months after. Symptoms and diabetes management improvement will be measured by the Gastroparesis Cardinal Symptom Index (GCSI) scores and the Diabetes Self-Management Questionnaire (DSMQ).
Intervention Type
Procedure
Intervention Name(s)
Pyloromyotomy
Intervention Description
Endoscopic Per-Oral Pyloromyotomy (POP)
Primary Outcome Measure Information:
Title
Change from Baseline in Hemoglobin A1C levels
Description
Glycemic control will be evaluated by measuring change in Hemoglobin A1C (HbA1c) levels. Poor glycemic control defined as an average HbA1c > 7.5%. Change = (Six Month Score - Baseline Score)
Time Frame
Baseline and 6 Month
Title
Change from Baseline in Glucose Levels measured by Continuous Glucose Monitor
Description
Glycemic control will be evaluated by measuring average glucose levels using Continuous Glucose Monitors (CGM). Normal glucose levels 74-99 mg/dL. Change = (Six Month Score - Baseline Score)
Time Frame
Baseline and 6 Month
Secondary Outcome Measure Information:
Title
Change from Baseline on Diabetes Self-Management Questionnaire
Description
The Diabetes Self-Management Questionnaire (DSMQ) is a self reported instrument assessing diabetes self-care activities. Possible scores range from 0 (Does not apply) to 3 (Applies to me very much). Change = (Six Month Score - Baseline Score)
Time Frame
Baseline and 6 Month
Title
Change from Baseline on Gastroparesis Cardinal Symptom Index
Description
The Gastroparesis Cardinal Symptom Index (GCSI) is a validated patient-administered questionnaire that is used to assess gastroparesis symptom severity. Possible scores range from 0 (None) to 5 (Very Severe). Change = (Six Month Score - Baseline Score)
Time Frame
Baseline and 6 Month

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients 18 years of age and older Patients with gastroparesis with an average HbA1c> 7.5% over the past 3 months Patient that have a diagnosis of gastroparesis established by documented delayed gastric emptying by either a wireless motility capsule study or a nuclear gastric emptying study, with no evidence of gastric obstruction. Patients are able to complete all study requirements Exclusion Criteria: Patients <18 years of age Patients with gastroparesis with an average HbA1c< 7.5% over the past 3 months Patients unable or refuse to complete the study requirements Patients who are unable or refuse to wear a CGM sensor Patients with insulin pumps Patients who already use a CGM
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Deanne Nash, RN
Phone
216-445-0953
Email
nashd@ccf.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mathew Allemang, MD
Organizational Affiliation
The Cleveland Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cleveland Clinic Foundation
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mathew Allemang, MD
Phone
216-491-7861
Email
ALLEMAM@ccf.org

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
19249393
Citation
Jung HK, Choung RS, Locke GR 3rd, Schleck CD, Zinsmeister AR, Szarka LA, Mullan B, Talley NJ. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology. 2009 Apr;136(4):1225-33. doi: 10.1053/j.gastro.2008.12.047. Epub 2008 Dec 24.
Results Reference
background
PubMed Identifier
30004920
Citation
Rodriguez J, Strong AT, Haskins IN, Landreneau JP, Allemang MT, El-Hayek K, Villamere J, Tu C, Cline MS, Kroh M, Ponsky JL. Per-oral Pyloromyotomy (POP) for Medically Refractory Gastroparesis: Short Term Results From the First 100 Patients at a High Volume Center. Ann Surg. 2018 Sep;268(3):421-430. doi: 10.1097/SLA.0000000000002927.
Results Reference
background
PubMed Identifier
21735078
Citation
Ramzan Z, Duffy F, Gomez J, Fisher RS, Parkman HP. Continuous glucose monitoring in gastroparesis. Dig Dis Sci. 2011 Sep;56(9):2646-55. doi: 10.1007/s10620-011-1810-z. Epub 2011 Jul 7.
Results Reference
background
PubMed Identifier
11469637
Citation
Tanenberg RJ, Pfeifer MA. Continuous glucose monitoring system: a new approach to the diagnosis of diabetic gastroparesis. Diabetes Technol Ther. 2000;2 Suppl 1:S73-80. doi: 10.1089/15209150050214168. No abstract available.
Results Reference
background
PubMed Identifier
25370149
Citation
Bailey TS, Chang A, Christiansen M. Clinical accuracy of a continuous glucose monitoring system with an advanced algorithm. J Diabetes Sci Technol. 2015 Mar;9(2):209-14. doi: 10.1177/1932296814559746. Epub 2014 Nov 3.
Results Reference
background
PubMed Identifier
30958664
Citation
Role of Continuous Glucose Monitoring in Diabetes Treatment. Arlington (VA): American Diabetes Association; 2018 Aug. Available from http://www.ncbi.nlm.nih.gov/books/NBK538971/
Results Reference
background
Links:
URL
http://www-ncbi-nlm-nih-gov.ccmain.ohionet.org/pmc/articles/PMC3722580/
Description
Clinical Guideline: Management of Gastroparesis [Internet]. [cited 2019 Aug 22].

Learn more about this trial

Impact of Per Oral Pyloromyotomy (POP) on Glycemic Control in Diabetes

We'll reach out to this number within 24 hrs